Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Down 88.1% in March

Estrella Immunopharma, Inc. (NASDAQ:ESLA) saw a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 4,900 shares, a decline of 88.1% from the February 29th total of 41,100 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average daily trading volume, of 45,400 shares, the days-to-cover ratio is currently 0.1 days.

Estrella Immunopharma Trading Down 0.8 %

Shares of ESLA stock traded down $0.01 during trading on Thursday, hitting $1.24. The company had a trading volume of 20,903 shares, compared to its average volume of 46,074. Estrella Immunopharma has a 52 week low of $0.86 and a 52 week high of $33.00. The business’s 50-day simple moving average is $1.12.

Estrella Immunopharma (NASDAQ:ESLA) last released its quarterly earnings results on Wednesday, February 14th. The company reported ($0.03) EPS for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Estrella Immunopharma stock. ATW Spac Management LLC purchased a new stake in Estrella Immunopharma, Inc. (NASDAQ:ESLA) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 40,000 shares of the company’s stock, valued at approximately $44,000. ATW Spac Management LLC owned approximately 0.11% of Estrella Immunopharma at the end of the most recent reporting period. Hedge funds and other institutional investors own 0.35% of the company’s stock.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.